Important resolutions of the annual board of directors 2022
- Home
- Important resolutions of the annual board of directors 2022
Important Resolutions of the Board of Directors in 2022 (Year 111)
▌Note: The table can be scrolled horizontally
| Date | Main Agenda | Resolution |
| 2022.03.18 | Agenda 1: The Company’s 2021 Financial Statements submitted for review. | With no objection from all attending directors, the proposal was approved. After accountants 林永智 and 田中玉 of PwC Taiwan complete the audit and certification of the 2021 financial statements, the case will be submitted to the shareholders’ meeting for acknowledgment. |
| Agenda 2: The Company’s 2021 Business Report and Statement of Loss Compensation submitted for discussion. | The proposal was approved with no objections and will be submitted to the shareholders’ meeting for acknowledgment. | |
| Agenda 3: Completion of the Company’s 2021 Internal Control Self-Assessment and issuance of the Internal Control System Statement submitted for discussion. | The proposal was approved with no objections from all attending directors. | |
| Agenda 4: Engagement of PwC Taiwan to conduct the 2022 financial statement audit, corporate income tax filing, and full-time non-managerial salary information submission submitted for discussion. | The proposal was approved with consent from all attending directors. | |
| Agenda 5: Amendments to certain provisions of the Company’s Articles of Incorporation submitted for discussion. | The proposal was approved with consent from all attending directors and will be included in the Annual Shareholders’ Meeting for discussion. | |
| Agenda 6: Amendments to the Company’s “Procedures for Acquisition or Disposal of Assets” submitted for discussion. | The amendments were approved with consent from all attending directors and will be included in the Annual Shareholders’ Meeting for discussion. | |
| Agenda 7: Full re-election of the Company’s directors submitted for discussion. | The proposal was approved with consent from all attending directors and will be submitted to the Annual Shareholders’ Meeting for election. | |
| Agenda 8: Arrangements for convening the 2022 Annual Shareholders’ Meeting submitted for discussion. | The proposal was approved with consent from all attending directors. | |
| 2022.04.29 | Agenda 1: The Company’s Q1 2022 Financial Report submitted for review. | The proposal was approved with no objections from all attending directors. |
| Agenda 2: Renewal of Directors’ Liability Insurance for 2022 submitted for discussion. | The proposal was approved with no objections from all attending directors. | |
| Agenda 3: Review of matters related to the nomination of three directors and four independent directors and explanation of their terms submitted for approval. | The qualification review and term explanation were approved with consent from all attending directors and will be submitted to the Annual Shareholders’ Meeting for election. | |
| 2022.06.10 | ||
| 2022.07.01 | Agenda 1: Completion of administrative procedures for appointing independent director 林能暉 as Independent Director, Audit Committee Member, and Remuneration Committee Member submitted for discussion. Extraordinary Motion: Independent Director 林能暉: Regarding the letter issued by the Taipei Exchange on 2022.06.20 requesting all independent directors to supervise the Company in accordance with the “Procedures for Verification and Public Disclosure of Material Information of TPEx-listed Companies,” submitted for discussion. |
The proposal was approved with consent from all attending directors. In accordance with Article 13 of the “National Central University External Employment Guidelines,” the Company and National Central University shall complete the execution of an industry-academia cooperation and academic contribution mechanism agreement within three months from 林能暉’s election on 06/10. The agreement shall take effect retroactively from the date of appointment. Additionally, with consent from all attending directors, it was approved that future material information disclosures shall emphasize balanced content and equal access to shareholder information to avoid unnecessary scrutiny from regulatory authorities. |
| 2022.07.29 | Agenda 1: The Company’s Q2 2022 Financial Report submitted for review. | The proposal was approved with consent from all attending directors. |
| Agenda 2: Confirmation of cooperation distributors for the Company’s high-bioavailability silymarin Hepanamin® products submitted for discussion. | The Company was approved to enter into a sales cooperation agreement with Ba Ma International Co., Ltd., with authorization granted to the Chairman to sign the contract. | |
| 2022.11.04 | Agenda 1: The Company’s Q3 2022 Financial Report submitted for discussion. | The proposal was approved with consent from all attending directors. |
| Agenda 2: Amendments to the Company’s “Procedures for Handling Material Inside Information” submitted for discussion. | The amendments were approved with consent from all attending directors. | |
| Agenda 3: Discussion of the commission fee adjustment for Mr. 陳一峰 submitted for discussion. | The proposal was approved with consent from all attending directors. | |
| 2022.12.16 | Agenda 1: Establishment of the Company’s 2023 Budget submitted for discussion. | The proposal was approved with consent from all attending directors. |
| Agenda 2: Establishment of the Company’s 2023 Audit Plan submitted for discussion. | The proposal was approved with consent from all attending directors. |